companydata.dkcompanydata.dk

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2013

CVR: 32323502

Source: annual report 2013, Danish Business Authority

01/01/2013 – 31/12/2013

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 18,483,731 and a net result of DKK 16,254,792. Equity in the 2013 report amounted to DKK 19,141,459. The solvency ratio was 16.5%.

Gross Profit
DKK 18,483,731
Profit/Loss
DKK 16,254,792
Equity
DKK 19,141,459
Total Assets
DKK 116,040,632

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2013

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S publishes interim reportJun 3, 2013

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its interim report for the period June 29, 2012 to December 31, 2012.

ACP 30.06.2012 1 A/S changes name to ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/SJan 30, 2013

On January 30, 2013, the company changed its name from ACP 30.06.2012 1 A/S to ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.

About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.

Source: annual report 2025, Danish Business Authority